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Chemical-shift and diffusion-weighted magnetic resonance imaging of thymus in myasthenia 
gravis: usefulness of quantitative assessment 
 
Abstract 
Objectives: To prospectively investigate the usefulness of chemical-shift (CS) and diffusion-
weighted (DW) magnetic resonance imaging (MRI) in patients with myasthenia gravis (MG) for 
distinguishing thymic lymphoid hyperplasia (TLH), normal thymus (NT) and thymoma (THY) by 
using the signal intensity index (SII) and the apparent diffusion coefficient (ADC). 
Materials and Methods: We evaluated 87 subjects (44 male, 43 female; range, 15-71years) with 
generalized MG and antibodies to the acetylcholine receptor seropositivity that underwent surgery. 
They were divided into a TLH/NT group (A, 64 patients; TLH, 49; NT, 15) and a THY group (B, 
24 patients; non-advanced THY, 15; advanced THY, 9), based on the histological findings. One 
patient with contemporary findings of TLH and non-advanced THY at histology was listed in both 
groups (87 subjects, 88 findings). CS-MRI was performed with dual-echo acquisition and the SII 
was measured for each subject. DW-MRI was performed at b values of 0, 150, 500, and 800 s/mm
2
, 
and the ADC value was obtained on the ADC-MAP after excluding the b 0 s/mm
2
 diffusion 
weighting. All measures were performed independently by two radiologists and inter-reader 
agreement was assessed by calculating the intraclass correlation coefficient (ICC). Differences on 
SII and ADC levels between groups and subgroups were tested using the Student-t test. Logistic 
regression models were estimated and discrimination abilities were individuated according to the 
Area Under the Receiver Operating Characteristic curve (AUROC). The optimal cut-points for 
differentiation of groups and subgroups were obtained by using the Youden Index. 
Results: The inter-reader agreement was excellent (ICC: SII=0.998; ADC=0.944). For CS-MRI, the 
mean SII value was significantly different between groups (A, 36.37%±12.60%; B, -0.06%±3.85%; 
p<0.001). No overlap in indexes was found with sensitivity, specificity, and cut-point of 100%, 
100%, and 6.37%, respectively. Conversely, the mean SII value was not different between 
subgroups of each group (A, p=0.607; B, p=0.252). For DW-MRI, The mean ADC values were 
significantly different between groups (A, 1.92±0.21 x 10
-3
 mm
2
/sec; B, 1.36±0.33 x 10
-3
 mm
2
/sec; 
p<0.001) and between subgroups of group A (TLH, 1.86±0.17 x 10
-3
 mm
2
/sec; NT, 2.10±0.23 x 10
-
3
 mm
2
/sec; p=0.002), although overlapped values were found. AUROC of ADC in discriminating 
TLH/NT from THY was 0.931 (95%CI: 0.863-0.998), and the optimal cut-point for this distinction 
was 1.625 x 10
-3
 mm
2
/sec (Youden Index, J=0.760) with sensitivity of 96.8% and specificity of 
79.2%. For subgroups of group A, AUROC of ADC in discriminating NT from TLH was 0.794 
(95%CI: 0.666-0.923), and the optimal cut-point for this distinction was 2.01 x 10
-3
 mm
2
/sec 
(Youden Index, J=0.458) with sensitivity of 66.7% and specificity of 79.2%. 
Conclusions: CS-MRI and DW-MRI are both useful tools for evaluating patients with MG. The SII 
is more accurate than the ADC to differentiate TLH and NT from THY (AUROC 1.000 and 0.931, 
respectively). Furthermore, the ADC is a non invasive parameter that could be used for 
distinguishing TLH from NT, which is useful in selecting patients for surgery since, for non-
thymomatous MG, acceptable rates of complete stable remission after thymectomy are found in 
TLH but not in NT. 
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INTRODUCTION 
Myasthenia gravis (MG) is a neurological autoimmune disorder caused by autoantibodies against 
components of the neuromuscular junction.
1
 The thymus is clearly involved in the pathogenesis of 
seropositive MG and is assumed to be one of the sources of anti-acetylcholine receptors (AChR) 
specific antibodies that are detectable in about 85% of patients with generalized MG.
1
 Indeed, at 
onset of MG, thymic lymphoid hyperplasia (TLH) can be found in up to 65% of patients, whereas a 
thymoma (THY) is detected in about 15% of patients.
2
 
Diagnostic imaging is crucial in order to detect the presence and type of thymic abnormality and for 
defining the proper management since surgical removal is recommended in all cases of THY.
1,2
 
Conversely, thymectomy is not always indicated in cases of TLH and should not be performed in 
cases of atrophic thymus or normal thymus (NT; with normal histological appearance and no 
germinal centres) since stable remission rates after extended thymectomy are significantly higher in 
TLH compared to NT or atrophic thymus.
2,3
 Hence, a highly reliable diagnostic imaging technique 
is needed to correctly differentiate these conditions. 
To date, computed tomography (CT) is the imaging modality of choice in evaluating the thymus of 
patients with new onset of MG,
2
 although it has limitations in distinguishing TLH from NT when 
TLH exhibits normal morphology and size within the limit of normal for a given patient’s age, a 
condition that occurs in 45% of subjects with TLH.
4
 In addition, CT cannot differentiate TLH from 
THY when TLH appears as a focal thymic mass (20% of cases) with soft tissue attenuation and no 
apparent fat content.
2,4,5
 
Magnetic resonance imaging (MRI) is not usually employed in clinical practice,
2
 and limited data 
are available on chemical-shift MRI from few studies with a small number of MG patients.
6,7
 
Chemical-shift imaging is more sensitive than CT for detecting fat in tissue and has been 
successfully used as quantitative technique, by calculating the signal intensity index (SII), to 
characterize lipid-poor adrenal adenomas that are indeterminate at CT.
8
 Thus, similarly, chemical-
shift MRI could be particularly useful in differentiating THY from focal TLH with soft tissue 
attenuation at CT. Moreover, diffusion-weighted (DW)-MRI could represent another useful tool to 
differentiate THY from non-thymomatous conditions (TLH and NT) and TLH from NT.
2
 Indeed, 
since DW-MRI reflects cell density and cellular architecture, it has been used in different organs, 
even in the thorax, for distinguishing benign from malignant lesions by calculating the apparent 
diffusion coefficient (ADC) that is significantly lower in malignant tumors.
9-11
 Nevertheless, 
currently, no study evaluated the reliability of DW-MRI in differentiating THY from non-
thymomatous conditions (TLH and NT) in MG patients. In addition, at present, no data are reported 
on the characterization of NT and on its distinction from TLH at DW-MRI, although TLH has 
typically a higher cellular density at histology compared to NT for the presence of germinal centres 
with lymphoid follicles and for an increased number of Hassall’s corpuscles.12 Thus, TLH could 
have lower ADC values than NT and DW-MRI could be helpful in this distinction. 
The aim of our study was to prospectively investigate the usefulness of chemical-shift and DW-
MRI in patients with generalized MG for distinguishing TLH, NT and THY by using the SII and 
ADC, with the proposal of the optimal cut-point value for each quantitative parameter, and whether 
these parameters are influenced by patients’ age.  
 
MATERIALS AND METHODS 
Patient Population 
An institutional review board approved the study, and informed consent was obtained from all 
subjects. In this prospective observational study conducted from January 2007 through December 
2013, all subjects with generalized MG that underwent extended thymectomy or thymomectomy 
were considered eligible for inclusion. Five subjects were excluded for contraindications to MRI 
(cardiac pacemaker and claustrophobia, 3 subjects) and patient refusal to enrollment (2 subjects). 
Hence, 87 consecutive subjects (44 men, 43 women; all subjects: age range 15-71ys, median age 
39ys, mean age ± standard deviation 38.6ys ± 11.8ys; male group: 18-68ys, 41ys, 40.6ys ± 20.1ys; 
female group: 15-71ys, 35ys, 36.5ys ± 13.0ys) were enrolled in this study and evaluated with MRI. 
The patients were assigned to two main groups based on the histological findings: a TLH/NT group 
(group A), that included 64 subjects, and a THY group (group B), that consisted of 24 patients 
(Table 1). One patient was listed in both groups because both TLH and non-advanced THY were 
found at histology after surgery (overall, 88 findings in 87 subjects). The mean age of patients in 
group A was lower than the mean age of those in group B and this age difference was statistically 
significant (36.5ys versus 44.2ys, respectively; p=0.009). For group B, according to the World 
Health Organization (WHO) histological classification of thymic epithelial tumors, overall we 
found 4 type A, 3 type AB, 5 type B1, 6 type B2, and 6 type B3 tumors. The more aggressive type 
of THY, type B3, was more frequently found in advanced THY subgroup (non-advanced THY: 1 
out of 15 cases, 6.7%; advanced THY: 5 out of 9 cases, 55.6%), and the significance of this 
difference was confirmed by performing the Fisher’s exact test (p=0.015). 
Proof of Diagnosis 
The histologic and histopathologic results from surgical specimens were the standard reference for 
all subjects. For the 64 subjects of group A, a histological confirmation of TLH and NT was 
obtained through extended thymectomy; hence, 49 cases of TLH and 15 cases of NT were 
identified. For the 24 patients of group B, the diagnosis was pathologically established by surgical 
removal (thymomectomy plus extended thymectomy); thus, 15 cases of non-advanced THY (stage 
I-II, including the patient with THY and TLH) and 9 cases of advanced THY (stage III-IV) were 
found according to the Masaoka-Koga staging system (Table 1). The median time between MRI 
and surgery was 19 days (range, 1-35 days). 
MR Imaging Protocol 
All exams were performed using a 1.5T unit (Intera-Achieva, Philips Healthcare, Best, The 
Netherlands) with the manufacturer’s 4-channel phased-array torso coil (Sense XL Torso; Philips 
Healthcare) for signal reception. MRI was performed to cover the entire chest, from the thoracic 
inlet to the cardiophrenic angle. 
Chemical-shift MRI: All patients underwent transverse gradient-echo T1-weighted in- and opposed-
phase imaging. The dual-echo acquisition, where both the in-phase and opposed-phase images were 
obtained in the same breath hold, was used for all patients. Other imaging parameters were as 
follows: 240-400 mm field of view, 256x256 image matrix, 5 mm section thickness, 0-0.5 mm 
intersection gap, flip angle 90
0
, repetition time 154 msec, and in-phase and opposed-phase echo-
times of 4.6 and 2.3 msec. For all exams, an anterior-to-posterior phase-encoding direction was 
used on the in-phase and opposed-phase images in order to avoid or minimize the presence of 
artifacts within the anterior mediastinum (chemical-shift of the first kind or spatial misregistration) 
at the lipid-water interface between the thymus or the lesion on one hand, and the great vessels or 
the chest wall on the other. However, we used a left-to-right phase-encoding direction if artifacts 
were detected within the lesion by using the anterior-to-posterior phase-encoding direction (i.e. 
large masses that widely protruded from the left or right side of the mediastinum). 
Diffusion-weighted MRI: DW imaging was performed using a single-shot spin-echo echo-planar 
sequence with the following parameters: 360-500 mm field of view, 116x224 image matrix, 45 echo 
planar imaging factor, 5 mm slice thickness, 0.5 mm intersection gap, 1600 msec repetition time, 62 
msec echo time, 1600 Hz/pixel bandwidth. Four signals were acquired per image with diffusion 
sensitizing gradients applied in three orthogonal planes (x, y, and z), in order to obtain isotropic 
diffusion weighting, and b values of  0, 150, 500, and 800 sec/mm
2
. All sequences were performed 
using a parallel imaging technique acquisition and SENSE (sensitivity encoding) reconstruction 
with a reduction factor (R) of 2. Fat was suppressed by placing a frequency-selective 
radiofrequency pulse before the pulse sequence. 
MR Image Analysis 
All exams were analyzed independently for qualitative and quantitative assessment by two 
radiologists (A.M.P. and D.G., each with 8 years of experience in thoracic MRI) who were unaware 
of the patients’ identification and clinical data. The image analysis was performed by using a 
Windows workstation (Dell, Xeon CPU 3.20 GHz) with dedicated software (Extended MR 
WorkSpace, version 2.6.3.1, 2009; Philips Healthcare, Best, The Netherlands). 
Chemical-shift MRI: For qualitative assessment, the readers determined whether the decrease in 
signal intensity of the thymus or the lesion was seen on the opposed-phase images relative to the in-
phase images. For quantitative assessment, the signal intensity measurements within the thymus or 
the mass were obtained with an electronic cursor, using regions of interest (ROI) of the same size, 
that was placed over the same position within the tissue on both in-phase and opposed-phase images 
in each case. The selection of the ROI placement was first made on the opposed-phase image, in 
order to avoid the inclusion of areas of signal void at the interfaces between the fat-dominant and 
water-dominant tissues (India ink artifact), and then mirrored on the in-phase image in the exact 
same position. On the opposed-phase T1-weighted image, the readers placed the ROI within the 
anterior mediastinal soft tissue that exhibited the highest signal intensity, avoiding cystic, necrotic, 
or calcified components. The SII was determined by comparing the signal intensity of the thymic 
tissue (tSI) on both in-phase (in) and opposed-phase (op) images by using the following equation: 
SII=[(tSIin–tSIop)/(tSIin)]x100%. 
Diffusion-weighted MRI: For qualitative assessment, the readers determined whether, in the thymus 
or the lesion, a persistent high signal or a signal attenuation were detected on images obtained with 
the higher b value of 800 s/mm
2
 or whether a complete signal suppression occurred at the lower b 
values of 150 or 500 s/mm
2
. For quantitative assessment, the ADC maps were reconstructed from 
the b 150, 500, and 800 s/mm
2
 images. The b 0 s/mm
2
 images were excluded from the 
reconstruction of the ADC maps and thus from the ADC computation to suppress tissue perfusion 
(the perfusion bias or “intravoxel incoherent motion”) in order to obtain perfusion-insensitive ADC 
values by eliminating the vascular contribution to the calculated ADC which would lead to an 
increase of the ADC value.
13-15
 For each patient, all the axial sections that included the lesion or the 
thymus (from 3 to 32 slices) were identified by using both DW sequences and ADC maps, 
chemical-shift images, and conventional T2-weighted images with and without fat suppression. 
Within each of these sections on the ADC maps, a ROI was defined using an electronic cursor along 
the circumference of the lesion or thymus, but within the boundaries. The ROI was manually drawn 
to include only the solid portion of the tissue, taking care to exclude obvious cystic and/or necrotic 
areas which were identified on the corresponding conventional T2-weighted images. The median 
ADC was calculated from all the ADC values obtained at each axial section of the tissue for each 
case and was used for further analyses. 
Statistical Analysis 
The Shapiro-Wilk test was performed and showed that the data were parametric with normal 
distribution. Hence, all data concerning SII and ADC levels, according to the defined groups and 
subgroups, were expressed as mean values ± standard deviations and ranges. Furthermore, they 
were also represented using box and whiskers plots. The inter-reader agreement of SII and ADC 
measurements was assessed by using the intraclass correlation coefficient (ICC, range: from 0 [no 
agreement] to 1 [perfect agreement]), calculated between the two readers. The SII and ADC values 
were then compared between groups and subgroups. The differences in SII and ADC levels 
between groups and subgroups were analyzed using the parametric Student-t test. Logistic 
regression models were estimated in order to evaluate the ability of SII and ADC levels to 
discriminate between groups (TLH/NT vs. THY) and between subgroups of group A (TLH vs. NT). 
The discrimination abilities were evaluated by the Area Under the Receiver Operating 
Characteristic (ROC) curve (AUROC) that was used to find the optimal SII and ADC cut-points. 
The optimal cut-points were determined according to the Youden Index with computation of 
sensitivity and specificity. Additional analyses aimed to control for age as a potential confounding 
factor were performed by including the age in logistic regression models. Furthermore, the 
correlation between both the quantitative parameters (SII and ADC) with age was evaluated by 
using the Pearson’s correlation coefficients. A p value of less than 0.05 was considered indicative of 
a statistically significant difference. All statistical analyses were performed with “R” software 
package (release 3.0.2; The R Foundation for Statistical Computing) . 
 
RESULTS 
Reliability of MRI in assessing the correct diagnosis 
One out of 87 cases with histological diagnosis of microscopic foci of TLH after extended 
thymectomy was excluded from the SII and ADC measurements because MRI demonstrated fatty 
involution of the thymus with no islands of soft tissue attenuation in the anterior mediastinum. 
Moreover, one subject was listed in both groups (A and B) because histology demonstrated non-
advanced THY and TLH, an association that was correctly suspected on chemical-shift MRI. Thus, 
MRI was able to define the correct diagnosis in 98.85% of cases (86 out of 87 subjects) in our 
cohort of patients with generalized MG that underwent surgery during the enrollment period. 
Nevertheless, MRI was able to differentiate perfectly between THY and benign conditions (TLH 
and NT) in all patients. 
Interobserver variability for quantitative and qualitative assessment 
For quantitative evaluations, the inter-reader agreement regarding both SII and ADC measurements 
was excellent with an ICC near to 1. The estimation of ICCs were 0.998 (95% confidence interval 
[95%CI]: 0.998-0.999) and 0.944 (95%CI: 0.915-0.963) for SII and ADC, respectively. Therefore, 
the mean SII and ADC value of the two readers was calculated for each case and used for further 
analyses. 
For qualitative evaluations, there was a perfect concordance between the two readers in assessing 
the presence or absence of signal intensity loss on opposed-phase images compared to in-phase 
images at chemical-shift MRI for all cases. Furthermore, a perfect concordance was also found in 
evaluating the complete signal suppression on DW images at different b values of 150, 500 and 800 
s/mm
2
 or the signal intensity persistence at the higher b value of 800 s/mm
2
. Hence in both cases it 
was not necessary to compute a statistical index of concordance. 
Quantitative analysis: differences of SII and ADC between groups and subgroups 
The mean values ± standard deviations of SII and ADC for the TLH/NT group (group A) and THY 
group (group B), and for subgroups of each group are reported in Table 2. For groups, the SII and 
ADC differed significantly between the two groups (p<0.001 for both quantitative parameters). For 
subgroups of each group, by evaluating the SII, no significant differences between subgroups were 
found in both groups (group A, p=0.607; group B, p=0.252). Conversely, the ADC was 
significantly different between subgroups of each group (group A, p=0.002; group B, p<0.001). 
Figures 1a and 1b show the box plots comparing the SII and ADC values for group A with those of 
group B, respectively. 
The logistic regression model for SII was not estimable since the value of 6.37% predicts group 
perfectly, with no overlap in range between groups (Figs. 1a and 1c), with an AUROC of 1.000. 
Thus, considering 6.37% as cut-point, for the diagnosis of THY and its differentiation from TLH 
and NT, sensitivity was 100% (24/24) and specificity was 100% (63/63). 
For DW-MRI, considering the logistic regression model for groups A and B, the tumor probability 
decreased with the increase of ADC (Odds Ratio [OR] per 0.01 increase, 0.91; 95%CI: 0.86-0.94). 
AUROC of ADC in discriminating between groups was 0.931 (95%CI: 0.863-0.998) (Fig. 2a). The 
optimal cut-point was identified in ADC value of 1.625 x 10
-3
mm
2
s
-1
 (Youden Index J=0.760). 
Applying this cut-point, for the diagnosis of TLH/NT, sensitivity was 96.8% (61/63, 95%CI: 92.7-
100) and specificity was 79.2% (19/24, 95%CI: 62.4-95.7). In the logistic model adjusted for age, 
OR was 0.89 per 0.01 ADC increase (95%CI: 0.83-0.94). Overlapped ADC values between group 
A and B were found in the range from 1.52 to 2.01 x 10
-3
mm
2
s
-1
 for 43 out of 63 (68.2%) subjects 
of group A and for 7 out of 24 (29.2%) patients of group B (Fig. 1b). 
For DW-MRI, considering the logistic regression model for subgroups of group A (TLH and NT), 
the probability of finding a NT increased with the increase of ADC (Odds Ratio [OR] per 0.01 
increase, 1.06; 95%CI: 1.03-1.11). AUROC of ADC in discriminating between subgroups of group 
A was 0.794 (95%CI: 0.666-0.923) (Fig. 2b). The optimal cut-point was identified in ADC value of 
2.01 x 10
-3
mm
2
s
-1
 (Youden Index J=0.458). Applying this cut-point, for the diagnosis of NT, 
sensitivity was 66.7% (10/15, 95%CI: 42.7-75.7) and specificity was 79.2% (38/48, 95%CI: 67.2-
90.8). In the logistic model adjusted for age, OR was 1.10 per 0.01 ADC increase (95%CI: 1.05-
1.17). Overlapped ADC values between NT and TLH were found in the range from 1.79 to 2.25 x 
10
-3
mm
2
s
-1
 for 11 out of 15 (73.3%) subjects of NT subgroup and for 28 out of 48 (58.3%) subjects 
of TLH subgroup (Fig. 1d). 
Quantitative analysis: relationship between SII-ADC and age 
We analyzed the correlation between both the quantitative parameters and the age of patients in 
order to search for potential influences of age on SII and ADC values. Figure 3 shows this 
relationship for each group. For chemical-shift MRI, when age was tested for its correlation with 
SII, a high significant positive correlation was found for group A (r=0.885, p<0.0001), but not for 
group B (r=0.245, p=0.249) (Figs. 3a and 3b, respectively); for DW-MRI, a mild positive 
correlation was found between ADC and age for group A (r=0.288, p=0.022), whereas the ADC did 
not vary with age in group B (r=0.235, p=0.269) (Figs. 3c and 3d, respectively). 
Qualitative analysis 
Chemical-shift MRI: at qualitative analysis, for group A, a homogeneous decrease in signal intensity 
of the thymus was detected on opposed-phase images relative to in-phase images in 61 out of 63 
(96.8%) subjects, namely in all patients of the NT subgroup (age range, 18-49ys), and in all patients 
but two of the TLH subgroup (age range, 15-71ys) (Fig. 4a). The two cases with no signal intensity 
loss visually appreciable on opposed-phase images were a 15-year-old woman and a 23-year-old 
man (SII of 7.77% and 12.66%, respectively), in which histology proved minimally fatty-infiltrated 
thymic tissue with many lymphoid follicles (Fig. 5a). No signal intensity loss was detected on 
opposed-phase images in any patients in the THY group (Fig. 6a). In addition, chemical-shift MRI 
successfully revealed a small rounded THY embedded in TLH in a 39-year-old man (SII of 0.64% 
with no decrease in signal intensity and 31.79% with signal intensity loss, respectively). 
Diffusion-weighted MRI: For group A, the ADC map demonstrated unrestricted diffusion by 
showing homogeneous bright appearance of the thymus in all subjects (Figs. 4b and 5b). In the 
same group, on native DW images obtained at different b values, a complete signal suppression was 
seen at the low b value of 150 s/mm
2
 in 52 out of 63 subjects (82.5%; 38/48 cases for TLH and 
14/15 cases for NT), at the intermediate b value of 500 s/mm
2
 in 11 out of 63 subjects (17.5%; 
10/48 cases for TLH and 1/15 cases for NT), but in none a persistent high or attenuated signal was 
maintained at the higher b value of 800 s/mm
2
 (Figs. 4c and 5c). For group B, the ADC map 
revealed homogeneous or inhomogeneous hypointensity within the lesion suggestive for restricted 
diffusion with no complete signal suppression at the higher b value of 800 s/mm
2
 in all cases (Fig. 
6b-c) but one. This last case (type AB THY) demonstrated complete signal suppression on the 
image obtained at b 800 s/mm
2
 with areas of bright appearance suggestive for unrestricted diffusion 
on the ADC map (ADC of 2.01 x 10
-3
mm
2
s
-1
). 
 
DISCUSSION 
MG is an autoimmune disorder of the neuromuscular junction characterized by muscle weakness, 
often initially involving the extrinsic ocular muscles and subsequently resulting in generalized MG 
in two-thirds of patients.
1
 The thymus has a role in the pathogenesis of MG that is highlighted by 
the presence of frequent histological abnormalities in patients with generalized MG, namely TLH 
and THY, and by the clinical benefit after thymectomy in certain conditions.
16
 Diagnostic imaging 
is crucial in all patients affected by MG for evaluating the presence of an underlying TLH or THY 
and for distinguishing these two conditions in order to select the proper therapeutic management, 
because the treatment strategies are different.
2,16,17
 Indeed, surgery is strongly recommended in 
patients with THY and represents the mainstay of the curative-intent treatment, since complete 
resection is the most significant positive prognostic factor, both on disease-free and overall 
survival.
18
 Conversely, in non-thymomatous MG, the primary therapeutic management is based on 
the use of acetylcholinesterase inhibitors and immunomodulatory agents.
1
 Lastly, an accurate 
imaging technique to differentiate THY from non-thymomatous conditions (TLH, NT, and atrophic 
thymus) is also required because, in a recent survey of current practice among members of the 
European Society of Thoracic Surgeons, 91% of centers declared to not routinely look for 
preoperative histological confirmation when CT strongly suggests a small thymoma with no 
apparent signs of invasion, especially if MG is associated.
18 
CT is currently considered the cross-sectional imaging technique of choice in the evaluation of 
patients with MG.
2,4,19
 At CT, differentiation of TLH from THY is mostly based on morphological 
and attenuation assessment because a normal CT appearance or a diffuse symmetric enlargement of 
the thymus with areas of fat attenuation represent the key morphologic features of hyperplasia (or 
even normal thymus if normal-sized), whereas a diagnosis of thymoma is suggested if a solid focal 
mass rather than a normal or diffusely enlarged thymus is detected.
2
 However, CT has limitations in 
distinguishing TLH from THY when TLH appears as a focal mass with homogeneous soft-tissue 
attenuation and no clear fatty infiltration, a condition that has been reported in 20% of cases in a 
cohort of 45 patients with MG.
4
 
Currently, MRI is not routinely employed in the evaluation of patients with MG, although it can 
provide more specific characterization compared to CT, especially in differentiating TLH from 
THY, regardless of morphologic assessment, by using chemical-shift imaging.
2
 Indeed, chemical-
shift MRI is able to detect microscopic fatty infiltration within the normal/hyperplastic thymus, 
which would be indistinct at CT, by showing homogeneous signal decrease on opposed-phase 
images relative to in-phase images, whereas signal loss is absent in THY that does not include 
fat.
6,20-22
 Nevertheless, only two previous studies with small sample size have used chemical-shift 
MRI to evaluate TLH and THY in patients with MG (overall, 15 patients: 5 TLH, 9 THY).
6,7
 Those 
studies demonstrated that all cases of TLH showed signal intensity loss on opposed-phase images, 
but none of patients with THY.
6,7
 Conversely, for qualitative assessment, in our cohort, we found no 
signal intensity loss on opposed-phase images in all patients with THY (as seen in previous studies) 
and in two cases of TLH, that were a 15-year-old girl and a 23-year-old man with minimally fatty-
infiltrated TLH at histology. For children and adolescents, this finding is consistent with a previous 
study that evaluated the fatty replacement of the normal thymus with chemical-shift MRI in 95 
healthy volunteers.
20
 Those investigators found that chemical-shift MRI can detect physiological 
fatty infiltration of the normal thymus in all subjects ≥16 years, in half of adolescents aged 10-16 
years, but in none <10 years, although a microscopic and gradually increasing amount of fat in the 
normal thymus exists from birth.
20
 In addition, a recent report described a case of non-suppressing 
normal thymus in a 21-year-old woman.
23
 Thus, similarly to the normal thymus, cases of non-
suppressing TLH at chemical-shift MRI may also occur in patients with MG, even in early 
adulthood, as seen in our study. Despite the imperfect reliability of chemical-shift MRI by visual 
assessment in distinguishing TLH from THY, by using SII for quantitative evaluation, we found no 
overlap in range of SII values between the two groups (TLH/NT versus THY) and a signal intensity 
loss of 7.77% or greater for TLH/NT group. In addition, the mean SII was significantly higher in 
TLH/NT group compared to THY group. Previous studies did not measure the SII in evaluating 
thymic abnormalities, because they did not use dual-echo single-breath-hold acquisition for 
chemical-shift imaging.
6,7
 Thus, the in-phase and opposed-phase images were separately obtained at 
chemical-shift MRI, and the signal intensity of the thymic abnormality (TLH and THY) or normal 
thymus was compared with that of the paraspinal muscles or chest wall muscles by using the 
chemical shift ratio (CSR) to assess any drop-out in signal intensity of the thymus between the two 
images.
6,7,20
 However, the CSR measurement, which is normalized to the paraspinal musculature, 
could be affected by age and body mass index, since subjects lose muscle mass as they age and the 
muscle has more fat interspersed between the muscle fiber bundles in older and/or overweight 
subjects.
6,24 
For this reason, in the present study, we preferred the use of dual-echo chemical-shift 
MRI, which does not require any normalization for its calculation, as used in previous studies for 
differentiating adrenal adenomas from non-adenomas.
8,24
 By using dual-echo chemical-shift MRI, 
considering the SII, we found a sensitivity and specificity of 100% in distinguishing TLH and NT 
from THY. Furthermore, in our study, quantitative evaluation was more accurate than qualitative 
analysis. Indeed, the two cases of TLH with no signal intensity loss at visual assessment had a 
signal intensity loss of 7.77% and 12.66% at quantitative evaluation. Hence, quantitative 
evaluations should always be performed in chemical-shift MRI, because qualitative analysis may be 
less sensitive than quantitative analysis for the characterization of TLH. 
DW-MRI did not show the perfect predictive ability of chemical-shift MRI for distinguishing TLH 
and NT from THY. Indeed, in the present study, we demonstrated a sensitivity of 96.8% and a 
specificity of 79.2% for this differentiation with an optimal ADC cut-point of 1.625 x 10
-3
mm
2
s
-1
, 
because an overlap in range of ADC values between groups was found. Nevertheless, the mean 
ADC value of TLH/NT group was significantly higher than that of THY group. Similarly to DW 
imaging studies in other oncologic applications, the ability of differentiating tumors from benign 
conditions is most likely due to the increased cellular density and vascularity in thymic epithelial 
tumors compared to TLH and NT (in which the variable fatty infiltration leads to a decrease of cell 
density), a condition that causes restriction to diffusion.
25
 To date, no study evaluated the ability of 
DW-MRI in differentiating TLH and NT from THY, and no data are reported on the 
characterization of NT (and relative ADC values) at DW imaging. Conversely, for THY and thymic 
hyperplasia, few data are available based on a limited number of patients enrolled in two different 
studies.
10,11
 Abdel Razek and colleagues demonstrated a lower mean ADC in eight patients with 
invasive THY compared to three cases of non-invasive THY (1.10±0.18 x 10
-3
mm
2
s
-1
 and 
2.00±0.11 x 10
-3
mm
2
s
-1
, respectively).
11
 Subsequently, in the study of Gumustas and colleagues, 
two cases of non-invasive THY and five cases of thymic hyperplasia were included, both grouped 
under benign conditions.
10
 Although they did not report the type of hyperplasia (rebound or 
lymphoid) nor the mean ADC value of each subgroup in benign group, the mean value for all 27 
benign lesions (that included various conditions) was 2.04±0.67 x 10
-3
mm
2
s
-1
.
10
 For non-advanced 
THY, we found lower ADC values (mean value, 1.53±0.25 x 10
-3
mm
2
s
-1
) compared to those 
reported for non-invasive THY in previous studies.
10,11
 This discordance could be related to the 
“perfusion bias” with a consequent overestimation in ADC measurements of those studies. Indeed, 
as both the investigators used also the images obtained with b values of 0 s/mm
2
 for the ADC 
computation, the ADC value was determined not only by diffusion (related to cell density and 
cellular architecture) but also by tissue perfusion. Blood flow may determine significant signal 
attenuation over the low b-value range (from 0 to 100  s/mm
2
), which artificially inflates diffusion 
estimates and thus may be mistakenly attributed to diffusion.
13,25-28 
In contrast with Abdel Razek, that distinguished Masaoka-Koga stage I disease (non-invasive THY) 
from higher stages (II-IV, invasive THY), we assessed whether DW-MRI could distinguish stage I-
II (non-advanced THY, no neo-adjuvant therapy before surgery required), from stage III-IV 
(advanced THY, neo-adjuvant treatments needed).
11
 Although we found a significantly higher mean 
ADC in non-advanced THY compared to advanced THY, this finding may have been influenced by 
the higher percentage of type B3 THY in advanced THY subgroup (56% versus 7% of non-
advanced THY subgroup). Indeed, the lower ADC values generally found in malignant tumors 
compared to benign conditions are related to a combination of higher cell density, tissue 
disorganization, and increased extracellular space tortuosity, all contributing to reduced motion of 
water.
13,25
 On these basis, lower ADC values can be expected in type B3 THY that is typically 
characterized by a prominent population of medium-sized polygonal epithelial cells and is the only 
histological type of THY that presents nuclear atypia and prominent nucleoli.
29
 This finding is 
similar to that obtained in a recent study by Benveniste and colleagues that evaluated the ability of 
2-[
18
F]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)-CT in 
differentiating non-advanced from advanced THY and THY from thymic carcinoma.
30
 Although no 
significant association was observed between higher focal FDG uptake and advanced THY, they 
found that FDG PET-CT is helpful in distinguishing thymic carcinoma and the more aggressive 
type B3 THY from the other histological types of THY.
30 
Albeit chemical-shift MRI is highly accurate in distinguishing TLH and NT from THY, it is not 
useful in differentiating TLH from NT. Indeed, in our study, the mean SII was not different between 
subgroups of group A (TLH and NT). This finding proves that the lipid content of the thymus is not 
different among TLH and NT in subjects of the same age group. In addition, in MG patients, TLH 
is morphologically indistinguishable from a NT when it has normal size for a given patient’s age 
and exhibits the typical triangular shape, a condition that occurs in 45% of MG patients with TLH.
4
 
The distinction between TLH and NT would be beneficial in patients with non-thymomatous MG 
and anti-AChR antibodies in order to select appropriately patients for surgery. Indeed, in non-
thymomatous MG, the clinical efficacy of thymectomy has been questioned because the evidence 
supporting its use is not clear and has largely been based on single-institution retrospective, 
observational studies.
3
 Currently, although no uniformly accepted guidelines are available, 
thymectomy is believed to be suitable for patients with generalized MG under 50 years with anti-
AChR antibodies and TLH, as an option to increase the probability of clinical improvement or 
complete stable remission.
16
 Contrariwise, effectiveness of extended thymectomy is still under 
discussion in patients with generalized MG and atrophic thymus or histological NT because the 
results of different studies are controversial, and stable remission rates up to 10 years of follow-up 
are significantly higher in TLH compared to NT or atrophic thymus in the majority of studies.
3,4
 To 
date, no study characterized the NT with DW imaging nor evaluated the ability of DW-MRI in 
differentiating TLH from NT. In the present study, the mean ADC of TLH was significantly lower 
than that of NT, although overlapped values were found. The lower ADC of TLH is probably 
related to its higher cellular density compared to NT, even for the presence of lymphoid germinal 
centres in the thymic medulla. Furthermore, a recent study by Matsui and colleagues demonstrated 
that the number of Hassall’s corpuscles per unit area of the thymic medulla is significantly higher in 
the thymuses of MG patients with TLH compared to MG patients with NT or THY.
12
 This new 
evidence suggests, once again, a higher cellular density and an increased number of prominent cells 
in TLH compared to NT that could explain the lower ADC values found in TLH. 
Another interesting finding of our research is the positive correlation between the quantitative 
parameters evaluated (SII and ADC) and age of patients in TLH/NT group. For chemical-shift MRI, 
it suggests a different amount of fatty tissue within the thymus that increases with age; for DW-
MRI, it is related to a gradually decreased cellular density in the thymus while age increases. 
Although these results are expected for the normal thymus and explained by the progressive fatty 
replacement and atrophy of the thymus with age, these findings could reflect for TLH a greater 
response of the thymus under the associated conditions (mostly autoimmune diseases, as MG) in 
younger subjects, with a lower amount of fat and an increased cellular density (lymphoid germinal 
centres and Hassall’s corpuscles) within the thymus, compared to elderly patients. 
Albeit chemical-shift MRI demonstrated a perfect reliability in differentiating THY from TLH and 
NT in our cohort, even in associated conditions of TLH and THY in the same patient, we found one 
case of discordance between MRI and histology. Indeed, in this case, while chemical-shift and DW-
MRI showed a thymus as entirely replaced by fat and classified as atrophic, the histological 
examination after thymectomy (surgery performed for clinical reasons and patient’s decision) 
diagnosed microscopic foci of TLH. Hence, MRI could have limitations for detecting microscopic 
foci of TLH and THY that are indistinguishable from mediastinal fat. 
The present study has some limitations. First, during the enrolment period, we did not include in our 
cohort all consecutive patients with onset of generalized MG, but only all consecutive patients that 
underwent surgical resection of the thymus in order to have histological examination as reference 
standard of diagnosis for all cases. This did not allow us to accurately assess sensitivity and 
specificity of MRI for detecting thymic abnormalities because patients with an atrophic thymus at 
CT and MRI, that were excluded from surgery, were not enrolled. Thus, we may have excluded 
other patients with microscopic foci of TLH or THY that presented an atrophic thymus at MRI. 
However, our primary endpoint was to evaluate the accuracy of MRI in differentiating TLH, NT 
and THY in patients with detectable thymic abnormalities. Second, we did not evaluate the cell 
count of a representative tissue block for each case in order to determine the number of cell/mm
2
. 
The demonstration of a significant negative correlation between cellularity and ADC in TLH/NT 
group, with higher ADC values for elderly patients compared to early adulthood, would have 
confirmed that cellular density in TLH decreases with increasing age. 
In conclusion, both chemical-shift MRI and DW-MRI are helpful tools for the evaluation of patients 
with generalized MG. The SII is a more accurate quantitative parameter than the ADC for 
distinguishing THY from TLH and NT. Nevertheless, for patients with non-thymomatous MG and 
anti-AChR antibodies, DW-MRI could represent an useful non-invasive method to differentiate 
non-enlarged TLH from NT in order to select appropriately patients for surgery, thus increasing 
chance of clinical improvement and complete stable remission. 
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Tables 
Table 1. Demographic Characteristics of the 87 Evaluated Patients § 
Group and Subgroup n § M/F ratio Age (years)* Size (mm)** 
Non-thymomatous conditions (group A) 
    Thymic lymphoid hyperplasia 
§
 
    Normal thymus 
64 
49 
15 
30/34 
23/26 
7/8 
36.5 [11.0] 
37.6 [11.0] 
33.1 [10.8] 
  12.6 [4.2]
 §§
 
  13.7 [4.0]
 §§
 
 8.9 [2.2] 
Thymomas (group B) 
    Non-advanced thymoma ***/
§
 
    Advanced thymoma *** 
24 
15 
9 
15/9 
9/6 
6/3 
44.2 [11.9] 
44.1 [12.1] 
44.3 [12.4] 
36.9 [26.6] 
23.0 [11.5] 
60.1 [28.9] 
n = number of patients; M = male; F = female. 
*/** Data are mean values [standard deviation]. 
** Size is the thickness of the thymus gland measured as the maximum dimension perpendicular to the long axis of each 
lobe for group A and the maximal diameter of the lesion for group B, measured on transverse images. 
*** Non-advanced thymoma = Masaoka-Koga stage I-II; advanced thymoma = Masaoka-Koga stage III-IV. 
§
 One subject is listed in both groups (final diagnosis of thymic lymphoid hyperplasia and non-advanced thymoma in the 
same patient after thymomectomy and extended thymectomy). 
§§
 Mean size obtained in 63 out of 64 patients (for group A) and in 48 out of 49 patients (for thymic lymphoid 
hyperplasia subgroup) after excluding one subject with a MRI appearance of complete fatty involution of the thymus 
(histological finding of microscopic foci of thymic lymphoid hyperplasia after extended thymectomy). 
 
Table 2. Mean SII and ADC of Groups A and B with Subgroups 
Parameter Groups or Subgroups p 
 
SII (%)* 
ADC (x 10
-3
mm
2
s
-1
)* 
Group A [63
§/§§
] 
36.37±12.60 (7.77/66.11) 
1.92±0.21 (1.52/2.53) 
Group B [24
§
] 
-0.06±3.85 (-7.95/6.37) 
1.36±0.33 (0.72/2.01) 
 
<0.001 
<0.001 
Group A 
SII (%)* 
ADC (x 10
-3
mm
2
s
-1
)* 
Thymic Lymphoid Hyperplasia [48
§/§§
] 
35.51±12.51 (7.77/60.40) 
1.86±0.17 (1.52/2.25) 
Normal Thymus [15] 
37.94±13.61 (15.69/66.11) 
2.10±0.23 (1.79/2.53) 
 
0.607 
0.002 
Group B 
SII (%)* 
ADC (x 10
-3
mm
2
s
-1
)* 
Non-advanced Thymoma** [15
§
] 
   -0.81±3.56 (-7.95/5.27) 
1.53±0.25 (1.13/2.01) 
Advanced Thymoma** [9] 
1.18±4.20 (-5.13/6.37) 
1.09±0.24 (0.72/1.48) 
 
0.252 
<0.001 
A = thymic hyperplasia/normal thymus group; B = tumor group; numbers in square brackets are number of patients. 
* Data are mean values ± standard deviations. Numbers in brackets are ranges. 
** Non-advanced thymoma = Masaoka-Koga stage I-II; advanced thymoma = Masaoka-Koga stage III-IV. 
§
 One subject is listed in both groups (MRI appearance of thymoma associated with thymic hyperplasia/normal thymus, 
confirmed after surgical removal). 
§§
 One subject with final diagnosis of microscopic foci of thymic lymphoid hyperplasia is excluded from the SII and 
ADC measurements because of the MRI appearance of complete fatty involution of the thymus. 
 
 
 
 
 
 
  
FIGURE LEGENDS 
FIGURE 1. Box-and-whiskers plots show the SII (a,c) and ADC (b,d) values for all cases divided 
into groups (a,b) and subgroups (c,d). The subgroups include subjects with thymic lymphoid 
hyperplasia (TLH) and normal thymus (NT) for group A, and patients with advanced thymoma 
(ATHY) and non-advanced thymoma (NATHY) for group B. The boxes represent data from the 
25
th
 to the 75
th
 percentile. The horizontal line inside the boxes is the median (50
th
 percentile). The 
vertical lines with whiskers indicate the range from the largest to smallest observed data point, 
within 1.5xIQR of the higher and lower quartile, respectively. The value outside this range (group 
A, NT) is displayed as an individual point. The continuous horizontal thick line in the graphs shows 
the optimal cut-point value for discrimination among groups deriving from the ROC analysis. For 
ADC, the horizontal thin line in graph d shows the optimal cut-point for differentiating subgroups 
of group A. Although a significant difference in ADC values between the two groups can be seen 
(p<0.001), an overlap zone is appreciable from 1.52 to 2.01 x 10
-3
mm
2
s
-1
 (area between dotted 
horizontal lines). Conversely, for SII, there are no overlapped values between the two groups. 
 
FIGURE 2. Receiver operating characteristic (ROC) curves indicate the sensitivity and specificity 
of ADC-based differentiation between groups (A vs. B) (a) and between subgroups of group A (NT 
vs. TLH) (b). For each curve, the optimal cut-off value is highlighted with the relative values of 
sensitivity and specificity. 
 
FIGURE 3. Graphs show for each group the relationship between SII and age for TLH/NT (a) and 
THY (b), and between ADC and age for TLH/NT (c) and THY (d) expressed by the Pearson’s 
correlation coefficient. Note the significant positive relationship between each quantitative 
parameter and age for group A (TLH/NT; a: SII, r=0.885, p<0.0001; c: ADC, r=0.288, p=0.022),  
but not for group B (THY; b: SII, r=0.245, p=0.249; d: ADC, r=0.235, p=0.269). Filled circles: 
TLH for group A, advanced THY for group B; empty circles: NT for group A; non-advanced THY 
for group B. 
 
FIGURE 4. A 41-year old woman with TLH. (a) Chemical-shift MRI shows a quadrilateral-shaped 
diffuse enlargement of the thymus anterior to the pulmonary trunk, with slightly convex lateral 
contours and a remarkable homogeneous decrease in signal intensity (arrows) on opposed-phase 
images relative to in-phase images (SII=38.18%). This finding proves the presence of fat within the 
thymus and suggests the diagnosis of a diffusely enlarged TLH. (b) The ADC map of DW-MRI 
shows unrestricted diffusion (ADC=2.11 x 10
-3
mm
2
s
-1
) (arrows). (c) DW imaging obtained at 
different b values shows a high and homogeneous hyperintensity of the thymus at b value of 0 
s/mm
2
 that gradually decreases at b values of 150 and 500 s/mm
2
 and is completely suppressed at 
the higher b value of 800 s/mm
2
 (arrows). (d) Photomicrograph of a representative histological 
section of TLH demonstrates (left image) areas of high cellular density that contain some lymphoid 
follicles with germinal centres (white asterisks) and Hassall’s corpuscles (arrows). The interstitial 
connective tissue is predominantly composed by extensive areas of fat cells (black asterisks) that 
decrease the cellular density per unit area. The magnification in the right image shows the 
morphology of a Hassall’s corpuscle within a context of high cell density (Hematoxylin and eosin 
stain; original magnification: x40 left image, x200 right image). 
 
FIGURE 5. A 15-year old girl with TLH. (a) Chemical-shift MRI shows a quadrilateral-shaped 
soft-tissue mass with slightly convex margins on the left side of the anterior mediastinum that has 
no apparent decrease in signal intensity (arrows) on opposed-phase images relative to in-phase 
images (SII=7.77%), suggesting the absence of fatty component. (b) The ADC map of DW-MRI 
shows unrestricted diffusion (ADC=1.86 x 10
-3
mm
2
s
-1
) (arrows; asterisks, aortic arch). (c) DW 
imaging obtained at different b values shows a high and homogeneous hyperintensity of the thymus 
at b value of 0 s/mm
2
 that gradually decreases at b values of 150 and 500 s/mm
2
 and is completely 
suppressed at the higher b value of 800 s/mm
2
 (arrows). (d) Photomicrograph of a representative 
histological section demonstrates minimally fatty-infiltrated thymic tissue with limited areas of fat 
cells (black asterisk) and lymphoid follicles with prominent germinal centres (white asterisks) 
(Hematoxylin and eosin stain; original magnification, x40). Although the SII demonstrates a 7.77% 
signal intensity decrease on opposed-phase images, the degree of fatty infiltration is not sufficient to 
determine a visually obvious decrease of signal intensity within the soft tissue mass. 
 
FIGURE 6. A 31-year old man with advanced THY (WHO type, B3). (a) Chemical-shift MRI 
shows an oval-shaped soft tissue mass in the left side of the anterior mediastinum, adjacent to the 
pulmonary trunk, with no change in signal intensity (arrows) on opposed-phase images relative to 
in-phase images (SII=1.77%), consistent with the absence of fat tissue. (b) The ADC map of DW-
MRI shows restricted diffusion (arrow) that suggests high density cellular tissue (ADC=0.72 x 10
-
3
mm
2
s
-1
). A mild bilateral pleural effusion is also seen (white asterisks). (c) DW imaging obtained 
at different b values detects a high heterogeneous hyperintensity of the lesion that is maintained at 
higher b values (arrows). (d) Photomicrograph of a representative histological section shows a 
tissue of high cellular density with no fat cells that is composed by medium-sized polygonal 
epithelial cells with mild atypia mixed with few lymphocytes (Hematoxylin and eosin stain; original 
magnification, x100). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
